View Older Stories View More Recent Stories

Mar 19, 2024 03:00AM PureTech Proposes $100 Million Capital Return
Mar 18, 2024 09:52AM Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
Mar 13, 2024 07:01AM PureTech Health (PRTC) Receives Orphan Drug Designation for LYT-200
Mar 13, 2024 07:00AM PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
Feb 27, 2024 07:00AM PureTech to Present at Two Upcoming Investor Conferences
Feb 27, 2024 05:57AM PureTech-Founded (PRTC) Akili (AKLI) Reports Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx
Feb 27, 2024 02:00AM PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Jan 3, 2024 07:00AM PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
Dec 22, 2023 09:13AM PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Dec 20, 2023 03:56AM PureTech Health Plc (PRTC) Issues Year End Update and Outlook for 2024
Dec 20, 2023 02:00AM PureTech Year End Update and Outlook for 2024
Dec 7, 2023 06:00AM PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
Nov 29, 2023 10:18AM PureTech Health (PRTC) Founded Entity Karuna Therapeutics (KRTX) Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Nov 29, 2023 10:17AM PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Nov 17, 2023 05:37AM PureTech Health (PRTC) Reports Karuna's (KRTX) Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Nov 17, 2023 02:00AM PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Nov 14, 2023 03:49AM PureTech Health (PRTC) Reports LYT-300 Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
Nov 14, 2023 02:00AM PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
Oct 17, 2023 02:00AM PureTech to Present at Two Upcoming Investor Conferences
Oct 11, 2023 07:00AM PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
Oct 4, 2023 07:05AM PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
Sep 28, 2023 07:38AM KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
Sep 27, 2023 05:49AM PureTech Health (PRTC) Appoints Robert Lyne as Chief Portfolio Officer
Sep 27, 2023 02:05AM PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
Aug 29, 2023 02:00AM PureTech Health plc – Half-Year Report
Aug 22, 2023 02:00AM PureTech Health: Notice of Half-Yearly Results
Aug 1, 2023 07:01AM PureTech (PRTC) Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
Aug 1, 2023 07:00AM PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
Jun 21, 2023 07:00AM PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders
Jun 13, 2023 12:40PM Results of PureTech's Annual General Meeting
May 9, 2023 02:00AM PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
May 4, 2023 02:00AM PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Ther
Apr 28, 2023 02:00AM PureTech Announces Annual Results for Year Ended December 31, 2022
Apr 25, 2023 06:50AM PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
Apr 17, 2023 07:05AM PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
Apr 13, 2023 02:00AM PureTech Health: Notice of Results
Mar 23, 2023 07:00AM Royalty Pharma (RPRX) and PureTech Health (PRTC) Enter KarXT Royalty Agreement for Up to $500M
Mar 23, 2023 07:00AM Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
Mar 23, 2023 03:00AM PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
Mar 1, 2023 07:00AM PureTech to Present at the Barclays Global Healthcare Conference
Feb 27, 2023 09:05AM PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impa
Feb 14, 2023 07:00AM PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression
Feb 1, 2023 07:00AM PureTech to Present at the SVB Securities Global Biopharma Conference
Dec 22, 2022 05:24AM PureTech Health (PRTC) Provides End of Year Update
Dec 22, 2022 02:00AM PureTech Provides End of Year Report on Key Progress
Dec 19, 2022 07:04AM PureTech's (PRTC) LYT-300 Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
Dec 19, 2022 07:00AM PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
Dec 13, 2022 07:00AM PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
Dec 12, 2022 09:00AM PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting
Dec 9, 2022 07:00AM PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring
View More Recent Stories View Older Stories